Remicade Eases Anxiety, Improves Quality of Life for Some Crohn’s Patients, China Study Finds

Remicade Eases Anxiety, Improves Quality of Life for Some Crohn’s Patients, China Study Finds
Remicade (infliximab) significantly benefitted the mental health of patients newly diagnosed with Crohn’s disease who had responded to the treatment, improving their perceptions of their illness and quality of life, and lowering anxiety levels, a recent study in China showed. These findings were published under the title “Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease” in the journal Patient Preference and Adherence. Crohn’s disease is a type of inflammatory bowel disease (IBD) commonly described as a chronic inflammation of any part of the gastrointestinal (GI) tract, though it most commonly pertains to inflammation of the small bowel, sometimes extending to the top layers of the large bowel. Patients with newly diagnosed Crohn’s often see their physical and emotional well-being compromised. These physical and psychological effects change throughout the course of the disease and may be influenced by medical treatment. Remicade, marketed by Janssen, is widely used to treat moderate-to-severe Crohn’s disease. The study's aim was to evaluate whether its use would also improve the psychological well-being of newly diagnosed Crohn's patients. A total of 82 patients completed the study at Ruijin Hospital, which is affiliated with  Sha
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *